

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16  
Under the Securities Exchange Act of 1934

For the Month of April 2016

001-36203  
(Commission File Number)

**CAN-FITE BIOPHARMA LTD.**

(Exact name of Registrant as specified in its charter)

**10 Bareket Street**  
**KiryatMatalon, P.O. Box 7537**  
**Petach-Tikva 4951778, Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover  
Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by  
Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by  
Regulation S-T Rule 101(b)(7): \_\_\_\_

This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795 and 333-209037), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

---

As previously disclosed, on April 5, 2016 Can-FiteBioPharma Ltd. (the “Company”) filed an application with the Lod District Court in Israel to approve the convening of a Special General Meeting of its Shareholders and a Special General Meeting of its Series 11 Warrant Holders to approve an extension of the term of the Company’s Series 11 Warrants until October 31, 2016 which is set to expire on April 30, 2016. As part of the application, the Company also requested the Court to extend the term of the Series 11 Warrants until June 30, 2016 as temporary relief. On April 11, 2016, the Court approved the Company’s application to extend the term of the Series 11 Warrants until June 30, 2016.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Can-FiteBioPharma Ltd.**

Date: April 13, 2016

By: /s/ Pnina Fishman  
Pnina Fishman  
Chief Executive Officer